白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2008年
2期
94-97
,共4页
张琦%张巧花%侯淑玲%王军%贺建霞%郭素堂%郑玉萍%韩维娥%王列样%杨斌
張琦%張巧花%侯淑玲%王軍%賀建霞%郭素堂%鄭玉萍%韓維娥%王列樣%楊斌
장기%장교화%후숙령%왕군%하건하%곽소당%정옥평%한유아%왕렬양%양빈
淋巴瘤,大细胞,弥漫型%乳酸脱氢酶%β2微球蛋白%CA125%光谱法,质量,基质辅助激光解吸电离
淋巴瘤,大細胞,瀰漫型%乳痠脫氫酶%β2微毬蛋白%CA125%光譜法,質量,基質輔助激光解吸電離
림파류,대세포,미만형%유산탈경매%β2미구단백%CA125%광보법,질량,기질보조격광해흡전리
Lymphoma,large-cell,diffuse%LDH%β2-MG%CA125%Spectrometry,mass,matrix-assisted laser desorption-inoization
目的 研究弥漫大B细胞淋巴瘤(DLBCL)患者血清蛋白质谱表达与淋巴瘤标志物的相关性,进一步研究该蛋白与DLBCL预后的关系.方法 SELDI技术WCX2芯片检测62例DLBCL患者蛋白质谱,生物化学方法测定乳酸脱氢酶(LDH),酶联免疫吸附法(ELISA)测定β2-微球蛋白(β2-MG)和癌抗原125(CA125).分析DLBCL患者11×103～12×103蛋白阳性组与阴性组间LDH、β2-MG、CA125的水平,同时作相关性分析及生存期分析.结果 11×103～12×103蛋白阳性组LDH、β2-MG、CA125水平分别为(523.30±435.96)U/L、(3.23±1.24)mg/L、(81.07±61.39)U/L,明显比阴性组高(P＜0.05).该蛋白峰值与LDH、β2-MG、CA125呈正相关(P＜0.01).该蛋白阳性组中位生存期11个月,生存期明显短于阴性组(P＜0.01).LDH正常组生存期明显长于增高组(P＜0.01),而β2-MG、CA125生存期差异无统计学意义.结论 11×103～12×103蛋白有望与LDH联合作为DLBCL患者的预后指标.
目的 研究瀰漫大B細胞淋巴瘤(DLBCL)患者血清蛋白質譜錶達與淋巴瘤標誌物的相關性,進一步研究該蛋白與DLBCL預後的關繫.方法 SELDI技術WCX2芯片檢測62例DLBCL患者蛋白質譜,生物化學方法測定乳痠脫氫酶(LDH),酶聯免疫吸附法(ELISA)測定β2-微毬蛋白(β2-MG)和癌抗原125(CA125).分析DLBCL患者11×103～12×103蛋白暘性組與陰性組間LDH、β2-MG、CA125的水平,同時作相關性分析及生存期分析.結果 11×103～12×103蛋白暘性組LDH、β2-MG、CA125水平分彆為(523.30±435.96)U/L、(3.23±1.24)mg/L、(81.07±61.39)U/L,明顯比陰性組高(P＜0.05).該蛋白峰值與LDH、β2-MG、CA125呈正相關(P＜0.01).該蛋白暘性組中位生存期11箇月,生存期明顯短于陰性組(P＜0.01).LDH正常組生存期明顯長于增高組(P＜0.01),而β2-MG、CA125生存期差異無統計學意義.結論 11×103～12×103蛋白有望與LDH聯閤作為DLBCL患者的預後指標.
목적 연구미만대B세포림파류(DLBCL)환자혈청단백질보표체여림파류표지물적상관성,진일보연구해단백여DLBCL예후적관계.방법 SELDI기술WCX2심편검측62례DLBCL환자단백질보,생물화학방법측정유산탈경매(LDH),매련면역흡부법(ELISA)측정β2-미구단백(β2-MG)화암항원125(CA125).분석DLBCL환자11×103～12×103단백양성조여음성조간LDH、β2-MG、CA125적수평,동시작상관성분석급생존기분석.결과 11×103～12×103단백양성조LDH、β2-MG、CA125수평분별위(523.30±435.96)U/L、(3.23±1.24)mg/L、(81.07±61.39)U/L,명현비음성조고(P＜0.05).해단백봉치여LDH、β2-MG、CA125정정상관(P＜0.01).해단백양성조중위생존기11개월,생존기명현단우음성조(P＜0.01).LDH정상조생존기명현장우증고조(P＜0.01),이β2-MG、CA125생존기차이무통계학의의.결론 11×103～12×103단백유망여LDH연합작위DLBCL환자적예후지표.
Objective To research correlation of serum protein spectrometry and lymphoma markers for diffuse large B cell lymphoma (DLBCL) patients. Whether there is relative between the protein and prognosis will be further researched. Methods Serum protein spectrometry of 62 DLBCL patients was detected by the SELDI-TOF-MS technique and Weak cation exchange 2 (WCX2) chip. Lactate dehydrogenase (LDH) was detected by biochemistry method. Beta-2-microglobulin (β2-MG) and cancer antigen125(CA125)were detected by enzyme-linked immunosorbent assay (ELISA). The level of LDH, β2-MG and CA125 for DLBCL patients between 11×103～12×103 protein expressed positively and negatively was analyzed. Meanwhile,correlation analysis and survival analysis were done. Results LDH, β2-MG and CA125 in 11×103～12×103protein expressed positive group were (523.30±435.96)U/L, (3.23±1.24)mg/L, (81.07±61.39)U/L respectively,and they were higher than that in negative group (P＜0.05). 11×103～12×103 protein was positive correlated to LDH, β2-MG and CA125 (P＜0.01). The survival time in 11×103～12×103 protein expressed in positive group,in which median survival time was 11 months, was shorter than that in negative group(P ＜0.01). The survival time in LDH normal group was longer than that in increased group(P ＜0.01). The survival time of β2-MG and CA125 had no significant difference between increased group and normal group. Conclusion LDH and 11×103～12×103 protein are expected to be prognosis indicators for DLBCL patients.
